By Dr John Walter Frew

Journal articles

Flora A; Jepsen R; Kozera E; Woods J; Cains G; Radzieta M; Malone M; Frew JW, 2023, '1323 Human dermal fibroblasts and mast cell populations are altered in hidradenitis suppurativa, with epithelial-mesenchymal-transition signals ameliorated by spleen tyrosine kinase antagonism.', Journal of Investigative Dermatology, 143, pp. S227 - S227, http://dx.doi.org/10.1016/j.jid.2023.03.1339

Jepsen R; Flora A; Kozera E; Frew JW, 2023, 'LB1700 SYK antagonism in hidradenitis suppurativa demonstrates clinical efficacy with grearter response in B-cell predominant disease: Results of a open-label, proof-of-concept phase 2 clinical trial', Journal of Investigative Dermatology, 143, pp. B15 - B15, http://dx.doi.org/10.1016/j.jid.2023.06.074

Tatian A; Bordbar S; Sarkissian SD; Woods JA; Cains GD; Chong CW; Mariño E; Frew JW, 2022, 'Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa', Experimental Dermatology, 31, pp. 1872 - 1880, http://dx.doi.org/10.1111/exd.14665

Kozera E; Flora A; Frew JW, 2022, 'Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study', Journal of the American Academy of Dermatology, 87, pp. 1440 - 1442, http://dx.doi.org/10.1016/j.jaad.2022.07.047

Mintoff D; Benhadou F; Pace NP; Frew JW, 2022, 'Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects', International Journal of Dermatology, 61, pp. 1175 - 1186, http://dx.doi.org/10.1111/ijd.15910

Ring HC; Yao Y; Maul JT; Ingram JR; Frew JW; Thorsen J; Nielsen ML; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A, 2022, 'The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study*', British Journal of Dermatology, 187, pp. 523 - 530, http://dx.doi.org/10.1111/bjd.21673

Ring HC; Frew JW; Thyssen JP; Egeberg A; Thomsen SF, 2022, 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?', Clinical and Experimental Dermatology, 47, pp. 1585 - 1586, http://dx.doi.org/10.1111/ced.15232

Navrazhina K; Frew JW; Grand D; Williams SC; Hur H; Gonzalez J; Garcet S; Krueger JG, 2022, 'Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum', British Journal of Dermatology, 187, pp. 223 - 233, http://dx.doi.org/10.1111/bjd.21060

Ring HC; Thorsen J; Fuursted K; Bjarnsholt T; Bay L; Egeberg A; Ingham AC; Vedel Nielsen H; Frew JW; Saunte DML; Thomsen SF; Jemec GB, 2022, 'Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls', Journal of the European Academy of Dermatology and Venereology, 36, pp. e580 - e583, http://dx.doi.org/10.1111/jdv.18075

Rick JW; De DR; Shih T; Alavi A; Kirby JS; Naik HB; Frew JW; Sayed CJ; Hsiao JL; Shi VY, 2022, 'Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts', Skin Appendage Disorders, 8, pp. 287 - 290, http://dx.doi.org/10.1159/000521268

Flora A; Frew JW, 2022, 'A case series of early biologic therapy in guttate psoriasis: Targeting resident memory T cell activity as a potential novel therapeutic modality', JAAD Case Reports, 24, pp. 82 - 87, http://dx.doi.org/10.1016/j.jdcr.2022.04.019

Kozera E; Stewart T; Gill K; De La Vega MA; Frew JW, 2022, 'Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study', British Journal of Dermatology, 186, pp. 1050 - 1052, http://dx.doi.org/10.1111/bjd.21019

Kozera EK; Kossard S; Frew JW, 2022, 'Extramammary Paget's disease Harbinger of internal malignancy', Australian Journal of General Practice, 51, pp. 351 - 352, http://dx.doi.org/10.31128/AJGP-05-21-5981

Navrazhina K; Renert-Yuval Y; Frew JW; Grand D; Gonzalez J; Williams SC; Garcet S; Krueger JG, 2022, 'Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*', British Journal of Dermatology, 186, pp. 684 - 693, http://dx.doi.org/10.1111/bjd.20642

Flora A; Kozera E; Frew JW, 2022, 'Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease', Experimental Dermatology, 31, pp. 498 - 515, http://dx.doi.org/10.1111/exd.14534

Frew JW, 2022, 'Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 142, pp. 747 - 749, http://dx.doi.org/10.1016/j.jid.2021.08.400

Frew JW, 2022, 'Dermatology and wound research: Targeting inflammation through cooperation and collaboration', Wound Practice and Research, 30, pp. 5, http://dx.doi.org/10.33235/wpr.30.1.5

Der Sarkissian S; Hessam S; Kirby JS; Lowes MA; Mintoff D; Naik HB; Ring HC; Suyien NC; Frew JW, 2022, 'Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review', JAMA Dermatology, 158, pp. 300 - 313, http://dx.doi.org/10.1001/jamadermatol.2021.4926

Yao Y; Frew JW; Thomsen SF; Ring HC, 2022, 'Antimicrobial peptides in hidradenitis suppurativa: a systematic review*', British Journal of Dermatology, 186, pp. 236 - 244, http://dx.doi.org/10.1111/bjd.20750

Navrazhina K; Garcet S; Frew JW; Zheng X; Coats I; Guttman-Yassky E; Krueger JG, 2022, 'The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris', Journal of the American Academy of Dermatology, 86, pp. 322 - 330, http://dx.doi.org/10.1016/j.jaad.2021.07.035

Naik HB; Alhusayen R; Frew J; Guilbault S; Hills NK; Ingram JR; Kudlinski MV; Lowes MA; Marzano AV; Paul M; Villumsen B; Yannuzzi CA, 2022, 'Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry', Journal of the American Academy of Dermatology, 86, pp. 249 - 252, http://dx.doi.org/10.1016/j.jaad.2021.09.016

Russell R; Slape D; McCrossin I; Frew JW, 2022, 'Cutaneous infection and atopic dermatitis: the importance of early intervention in Indigenous children in Australia', Wound Practice and Research, 30, pp. 34 - 39, http://dx.doi.org/10.33235/wpr.30.1.34-39

Navrazhina K; Garcet S; Zheng X; Hur HB; Frew JW; Krueger JG, 2022, 'High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression', Journal of Allergy and Clinical Immunology, 149, pp. 135 - 144.e12, http://dx.doi.org/10.1016/j.jaci.2021.05.027

Honigman A; Kern JS; Frew JW, 2022, 'Pathergy: a review of potential mechanisms and novel therapeutic targets', Wound Practice and Research, 30, pp. 55 - 61, http://dx.doi.org/10.33235/wpr.30.1.55-61

Flora A; Frew JW, 2022, 'Pyoderma gangrenosum: a review of the clinical, mechanistic and therapeutic landscape', Wound Practice and Research, 30, pp. 16 - 23, http://dx.doi.org/10.33235/wpr.30.1.16-23

Kozera EK; Frew JW, 2022, 'The pathogenesis of hidradenitis suppurativa: Evolving paradigms in a complex disease', Dermatological Reviews, 3, pp. 39 - 49, http://dx.doi.org/10.1002/der2.113

Frew JW; Grand D; Navrazhina K; Garcet S; Krueger JG, 2021, 'Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa', Journal of the European Academy of Dermatology and Venereology, 35, pp. e884 - e887, http://dx.doi.org/10.1111/jdv.17536

Stewart T; Cachia A; Frew J, 2021, 'Cellular neurothekeoma', International Journal of Women's Dermatology, 7, pp. 835 - 837, http://dx.doi.org/10.1016/j.ijwd.2021.07.011

Kozera EK; Lowes MA; Hsiao JL; Frew JW, 2021, 'Clinical considerations in the management of hidradenitis suppurativa in women[Formula presented]', International Journal of Women's Dermatology, 7, pp. 664 - 671, http://dx.doi.org/10.1016/j.ijwd.2021.10.012

Williams SC; Frew JW; Krueger JG, 2021, 'A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa', Experimental Dermatology, 30, pp. 1388 - 1397, http://dx.doi.org/10.1111/exd.14141

Tatian A; Slape D; Lawless R; Frew JW, 2021, 'A systematic review of reported cases of pachyonychia congenita tarda (vol 44, pg 606, 2019)', CLINICAL AND EXPERIMENTAL DERMATOLOGY, 46, pp. 1395 - 1395, http://dx.doi.org/10.1111/ced.14864

Frew JW; Alavi A; Kirby JS, 2021, 'An Abscess Is Not a Descriptive Term but an Entity with a Universally Accepted Definition - A Clarification on Semantics - Reply', JAMA Dermatology, 157, pp. 1245 - 1246, http://dx.doi.org/10.1001/jamadermatol.2021.2495

Frew JW, 2021, 'Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic', British Journal of Dermatology, 185, pp. 696 - 697, http://dx.doi.org/10.1111/bjd.20513

Frew JW, 2021, 'Differential profiles of gamma secretase Notch signalling in hidradenitis suppurativa: the need for genotype–endotype–phenotype analysis', British Journal of Dermatology, 185, pp. 636 - 637, http://dx.doi.org/10.1111/bjd.19805

Navrazhina K; Garcet S; Gonzalez J; Grand D; Frew JW; Krueger JG, 2021, 'In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes', Journal of Investigative Dermatology, 141, pp. 2197 - 2207, http://dx.doi.org/10.1016/j.jid.2021.02.742

Flora A; Holland R; Smith A; Frew JW, 2021, 'Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)', JAAD Case Reports, 14, pp. 33 - 36, http://dx.doi.org/10.1016/j.jdcr.2021.05.029

Der Sarkissian S; Frew JW, 2021, 'Ultrasound-guided de-roofing of epithelialised tunnels of hidradenitis suppurativa', Australasian Journal of Dermatology, 62, pp. 360 - 363, http://dx.doi.org/10.1111/ajd.13600

Frew JW; Singh N; Jiang CS; Vaughan R; Krueger JG, 2021, 'The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa', Frontiers in Medicine, 8, http://dx.doi.org/10.3389/fmed.2021.603281

Navrazhina K; Frew JW; Gilleaudeau P; Sullivan-Whalen M; Garcet S; Krueger JG, 2021, 'Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa', Journal of Allergy and Clinical Immunology, 147, pp. 2213 - 2224, http://dx.doi.org/10.1016/j.jaci.2020.12.651

Zouboulis CC; Frew JW; Giamarellos-Bourboulis EJ; Jemec GBE; del Marmol V; Marzano AV; Nikolakis G; Sayed CJ; Tzellos T; Wolk K; Prens EP, 2021, 'Target molecules for future hidradenitis suppurativa treatment', Experimental Dermatology, 30, pp. 8 - 17, http://dx.doi.org/10.1111/exd.14338

Grand D; Frew JW; Navrazhina K; Krueger JG, 2021, 'Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity', British Journal of Dermatology, 184, pp. 688 - 696, http://dx.doi.org/10.1111/bjd.19343

Frew JW; Lowes MA; Goldfarb N; Butt M; Piguet V; O'Brien E; Ingram J; Jemec GBE; Tan J; Zouboulis C; Alavi A; Kirby JS, 2021, 'Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary', JAMA Dermatology, 157, pp. 449 - 455, http://dx.doi.org/10.1001/jamadermatol.2020.5467

Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG, 2021, 'Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab', Clinical and Experimental Dermatology, 46, pp. 306 - 313, http://dx.doi.org/10.1111/ced.14448

Frew J; Penzi L; Suarez-Farinas M; Garcet S; Brunner PM; Czarnowicki T; Kim J; Bottomley C; Finney R; Cueto I; Fuentes-Duculan J; Ohmatsu H; Lentini T; Yanofsky V; Krueger JG; Guttman-Yassky E; Gareau D, 2021, 'The erythema Q-score, an imaging biomarker for redness in skin inflammation', Experimental Dermatology, 30, pp. 377 - 383, http://dx.doi.org/10.1111/exd.14224

Frew JW; Marzano AV; Wolk K; Join-Lambert O; Alavi A; Lowes MA; Piguet V, 2021, 'A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance', Journal of Investigative Dermatology, 141, pp. 316 - 324.e2, http://dx.doi.org/10.1016/j.jid.2020.06.019

van Straalen KR; Frew JW, 2021, 'The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa', Journal of Investigative Dermatology, 141, pp. 429 - 431, http://dx.doi.org/10.1016/j.jid.2020.03.977

Frew JW; Navrazhina K; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Krueger JG, 2021, 'Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study', British Journal of Dermatology, 184, pp. 350 - 352, http://dx.doi.org/10.1111/bjd.19478

Frew JW; Krueger JG, 2021, 'What's in the pipeline for hidradenitis suppurativa? Emerging and novel therapeutics', Drugs of the Future, 46, pp. 43 - 60, http://dx.doi.org/10.1358/DOF.2021.46.1.3220744

Williams S; Navrazhina K; Frew J; Garcet S; Krueger JG, 2021, '700 Vascularization in the deep dermis of hidradenitis suppurativa lesions', Journal of Investigative Dermatology, 141, pp. S121 - S121, http://dx.doi.org/10.1016/j.jid.2021.02.730

Navrazhina K; Renert-Yuval Y; Frew J; Grand D; Garcet S; Krueger JG, 2021, '703 Blood analysis uncovers novel inflammatory, oncologic and cardiovascular biomarkers in psoriasis and Hidradenitis Suppurativa', Journal of Investigative Dermatology, 141, pp. S122 - S122, http://dx.doi.org/10.1016/j.jid.2021.02.733

Back to profile page